A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer
RNA-seq (gene expression) · human · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 20 samples: 10 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerOncogene · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE255593_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1075686 and SRA study SRP489412. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 10 replicated groups read from 20 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8075681 22RV1_T0 22RV1_T
- GSM8075682 22RV1_T6_Rep01 22RV1_T6
- GSM8075683 22RV1_T6_Rep02 22RV1_T6
- GSM8075684 22RV1_T12_Rep01 22RV1_T12
- GSM8075685 22RV1_T12_Rep02 22RV1_T12
- GSM8075686 22RV1_NMYC_T0 22RV1_NMYC_T
- GSM8075687 22RV1_NMYC_T6_Rep01 22RV1_NMYC_T6
- GSM8075688 22RV1_NMYC_T6_Rep02 22RV1_NMYC_T6
- GSM8075689 22RV1_NMYC_T12_Rep01 22RV1_NMYC_T12
- GSM8075690 22RV1_NMYC_T12_Rep02 22RV1_NMYC_T12
- GSM8075703 22RV1_T0 22RV1_T
- GSM8075704 22RV1_T7_REP1 22RV1_T7
- GSM8075705 22RV1_T7_REP2 22RV1_T7
- GSM8075706 22RV1_T13_REP1 22RV1_T13
- GSM8075707 22RV1_T13_REP2 22RV1_T13
- GSM8075708 22RV1_NMYC_T0 22RV1_NMYC_T
- GSM8075709 22RV1_NMYC_T7_REP1 22RV1_NMYC_T7
- GSM8075710 22RV1_NMYC_T7_REP2 22RV1_NMYC_T7
- GSM8075711 22RV1_NMYC_T13_REP1 22RV1_NMYC_T13
- GSM8075712 22RV1_NMYC_T13_REP2 22RV1_NMYC_T13
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing · shares plasticity
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE302864 DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer 12 samples shares neuroendocrine, plasticity, prostate
- GSE230601 ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer [RNA-seq] 12 samples shares plasticity, prostate, driven
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.